Please assess the completion status of the following clinical trial:

Trial Title: Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Clinical diagnosis of Parkinson's disease: Gibb and Gelb criteria~* Apathy defined by a score of - 16 or more on the LARS scale (Sockeel et al., 2006)and criteria of Marin (1991)~* No dementia according to DSM IV with MMSE Score≥ 27 and Mattis score≥ 130~* Under stable dopaminergic treatment for 3 months~Exclusion criteria:~* Depression according to DSM-IV criteria and a score \< 18 on the MADRS~* Subthalamic stimulation of less than one year~* Subthalamic stimulation without stable parameters for 3 months~* Subject older than 80 years~* Severe rest tremor with a subscore \> or= 3 on the UPDRS part~* Parkinson related Psychosis in progress~* Hypersensibility to cholinesterase inhibitors or carbamates~* Myocardial infarction, other cardiac affections~* Severe hepatic insufficiency~* Sever medical illness~* Skin diseases interfering with transdermal patch~* Pregnancy~* Incapacity to give the consent

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Active treatment (Type: ACTIVE_COMPARATOR): A: transdermal rivastigmine at 4.6 mg per day during one month then 9.5 mg per day during 5 months.
- placebo (Type: PLACEBO_COMPARATOR): transdermal patch of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).